(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of strong sales for its blockbuster cancer drug Keytruda, sending the company's shares up more than 2% before the bell. Keytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward the end of the decade. The drug is seeing growth from use for additional types of cancers as well as higher patient demand, Chief Financial Officer Caroline Litchfield said.
Updated Kansas revenue projections will influence Gov. Laura Kelly's decision this week on state tax and budget bills passed by GOP-led Legislature. The post Kansas analysts update revenue forecast ahead of Gov. Laura Kelly’s decision on tax, budget bills appeared first on Kansas Reflector.